

Motegrity[™] (prucalopride) – New drug approval

- On December 17, 2018, <u>Shire announced</u> the FDA approval of <u>Motegrity (prucalopride)</u>, for the treatment of chronic idiopathic constipation (CIC) in adults.
- CIC is a common condition affecting roughly 14% of the adult population. Symptoms can range from straining and bloating, to infrequent, or incomplete bowel movements. It is believed that CIC may be caused by insufficient movement of the colon muscle.
- Motegrity, a selective serotonin type (5-HT₄) receptor agonist, is a gastrointestinal prokinetic agent that stimulates colonic peristalsis (contractions), which increases bowel motility.
- The efficacy of Motegrity for the treatment of CIC was evaluated in six placebo-controlled studies in 2,484 adult patients. Studies 1 through 5 were 12-weeks and study 6 was 24 weeks. The primary efficacy endpoint was defined as a patient with an average of 3 or more complete, spontaneous bowel movements per week, over the 12-week treatment period.

	Efficacy Responder Rates			
Study	Motegrity	Placebo	Treatment Difference (95% CI)	p value
Study 1	33%	10%	23 (16, 30)	p < 0.001
Study 2	38%	18%	20 (11, 29)	p < 0.001
Study 3	19%	10%	10 (4, 16)	p = 0.002
Study 4	29%	13%	16 (8, 24)	p < 0.001
Study 5	24%	12%	12 (4, 19)	p < 0.001
Study 6	25%	20%	5 (-4, 14)	p = 0.341

- Motegrity is contraindicated in patients with hypersensitivity to Motegrity and in patients with
 intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive
 ileus, and severe inflammatory conditions of the intestinal tract such as Crohn's disease, ulcerative
 colitis, and toxic megacolon/megarectum.
- A warning and precaution of Motegrity includes suicidal ideation and behavior.
- The most common adverse reactions (≥ 2%) with Motegrity use are headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, and fatigue.
- The recommend dose of Motegrity is 2 mg orally once daily, with or without food.
- Shire plans to launch Motegrity in 2019. Motegrity will be available as 1 mg and 2 mg tablets.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.